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Background: Dysuria following prostate radiation therapy is a common toxicity that 
adversely affects patients’ quality of life and may be difficult to manage.
Methods: Two hundred four patients treated with stereotactic body radiation therapy 
(SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow-up 
of 3 years were included in this retrospective review of prospectively collected data. All 
patients were treated to 35–36.25 Gy in five fractions delivered with robotic SBRT with real 
time fiducial tracking. Dysuria and other lower urinary tract symptoms were assessed via 
Question 4b (Pain or burning on urination) of the expanded prostate index composite-26 
and the American Urological Association (AUA) Symptom Score at baseline and at routine 
follow-up.
results: Two hundred four patients (82 low-, 105 intermediate-, and 17 high-risk accord-
ing to the D’Amico classification) at a median age of 69 years (range 48–91) received 
SBRT for their localized prostate cancer with a median follow-up of 47 months. Bother 
associated with dysuria significantly increased from a baseline of 12% to a maximum 
of 43% at 1 month (p < 0.0001). There were two distinct peaks of moderate to severe 
dysuria bother at 1 month and at 6–12 months, with 9% of patients experiencing a late 
transient dysuria flare. While a low level of dysuria was seen through the first 2 years of 
follow-up, it returned to below baseline by 2 years (p = 0.91). The median baseline AUA 
score of 7.5 significantly increased to 11 at 1 month (p < 0.0001) and returned to 7 at 
3 months (p = 0.54). Patients with dysuria had a statistically higher AUA score at baseline 
and at all follow-ups up to 30 months. Dysuria significantly correlated with dose and AUA 
score on multivariate analysis. Frequency and strain significantly correlated with dysuria 
on stepwise multivariate analysis.
conclusion: The rate and severity of dysuria following SBRT is comparable to patients 
treated with other radiation modalities.
Keywords: dysuria, prostate cancer, stereotactic body radiation therapy, aUa, expanded prostate index 
composite, cyberKnife, quality of life
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introduction
Over 200,000 men were diagnosed with prostate cancer in the 
United States in 2014, making prostate cancer the most common 
cancer in men (1). Localized prostate cancer is typically treated 
with either surgery or radiation, with external beam radiation 
therapy (EBRT) and brachytherapy being the most commonly 
utilized radiation treatment modalities. Selection of treatment 
modality depends on a number of factors, including age, perfor-
mance status, risk stratification, and patient preference. As prostate 
cancer is associated with a high-cure rate and a long natural his-
tory, treatment side effects may have a large impact on quality of 
life (QOL). Indeed, studies have revealed that patient desire for 
curative therapy can be heavily influenced by treatment-related 
changes in QOL (2, 3).
Urinary symptoms are a primary determinate of QOL fol-
lowing prostate radiotherapy (4). Dysuria is a clinical problem 
associated with benign prostatic enlargement (BPH) and/or 
prostatitis (5). It is a commonly reported toxicity following pelvic 
radiation therapy and may be difficult to manage (6). Patients 
with radiation-induced dysuria describe symptoms of burning 
or pain with urination. The etiology of radiation-induced dysuria 
is unknown, but may involve inflammation and mucosal loss at 
the urethra and bladder neck (6). The risk of dysuria appears to 
be dependent upon a number of factors, including the prostate 
volume, the volume of the urethra receiving a high-radiation dose, 
and delayed use of alpha-blockers (7, 8).
Dysuria is often an acute symptom that peaks within the first few 
months following treatment and resolves with time (4). Accurate 
capture of the patient reported experience is heavily dependent 
on the assessed time points, with some reports potentially missing 
the full extent of dysuria when the first assessment is not within 
the first weeks to month post-treatment (4, 9). Other factors that 
may influence the reporting of dysuria include the severity of 
the symptom, with only the most severe symptomatology being 
reported, and the questions utilized to capture the data, with only 
some forms having specific questions related to dysuria.
Despite the complexities of capturing dysuria information and 
inter-researcher differences in data capture techniques, there does 
appear to be differences in both the severity and the temporal 
aspects of the peak and resolution of dysuria dependent upon 
the radiation technique employed (4, 10). Following convention-
ally fractionated EBRT, the frequency of moderate to severe 
dysuria is 12, 5, and 1% at 2, 6, and 12 months post-treatment, 
respectively (4). In comparison, brachytherapy patients reported 
moderate to severe dysuria frequency of 24, 11, and 11% at 2, 6, 
and 12 months, respectively (4). Indeed, dysuria is a commonly 
reported side effect of brachytherapy treatment (9, 11–13), with 
frequencies of up to 85–88% at 1 month following treatment (9, 
13), decreasing to 50% at 6 months (9). For men who reported 
dysuria after brachytherapy, the dysuria persisted for 36 months 
prior to resolution (14). While urethral dose has been shown to be a 
statistically significant predictor of urinary morbidity (15), studies 
looking specifically at clinical, treatment, and dosimetric variable 
predictors of brachytherapy-related dysuria have failed to dem-
onstrate significance (9, 14). Only higher post-implant American 
Urological Association (AUA) scores significantly predicted for 
dysuria (14). Merrick et al. showed that prophylactic tamsulosin 
significantly reduced dysuria rates after brachytherapy (9), and 
Prosnitz et al. showed that tamsulosin relieved the symptoms of 
radiation urethritis after EBRT (16).
Radiation dosing and fractionation for the curative treatment 
of prostate cancer are  areas of active clinical investigation. While 
standard radiation dosing involves daily treatment for 8–9 weeks, 
stereotactic body radiation therapy (SBRT) allows treatment over 
a shorter time span, with delivery of fewer, high-dose fractions of 
radiation. Early data from trials of SBRT for treatment of local-
ized prostate cancer show SBRT to be safe and effective (17–25). 
However, it is still uncertain whether the use of large fraction sizes 
could increase the incidence and severity of urinary morbidity, 
such as dysuria. The goal of this study is to report the incidence 
and severity of dysuria following SBRT for prostate cancer.
Materials and Methods
Patient selection
Eligible patients included those with histologically confirmed 
prostate cancer without evidence of involved lymph nodes, clinical 
stage T3 disease, distant metastases, and/or prior pelvic radiation. 
Quality of life (QOL) data were prospectively collected for all 
patients per our institutional protocol. This study was performed 
with full Internal Review Board (IRB) approval.
sBrT Treatment Planning and Delivery
Our institutional SBRT treatment planning and delivery has 
been previously described (17, 26). Briefly, several days after 
placement of three to four gold markers, the patients underwent 
magnetic resonance (MR) and computed tomography (CT) 
imaging. The MR and CT images were then fused and used for 
treatment planning. The prostate and proximal seminal vesicles 
made up the clinical target volume (CTV); this volume was then 
expanded 3 mm posteriorly and 5 mm in all directions to define 
the planning target volume (PTV). Patients were treated with 
our institutional SBRT monotherapy protocol to 35–36.25 Gy 
in five fractions of 7–7.25 Gy prescribed to the PTV; the tumor 
equivalent dose in 2 Gy fractions (EQD2) is 85–90 Gy assuming 
an alpha/beta ratio of 1.5.
Plans were inhomogeneous by design to minimize dose to adja-
cent critical structures. Dose–volume histogram (DVH) analysis of 
Abbreviations: ADT, androgen deprivation therapy; AUA, American Urological Association; BPH, benign prostatic hypertrophy; CT, computed 
tomography; CTV, clinical target volume; DVH, dose-volume histogram; EBRT, external beam radiation therapy; EPIC, expanded prostate index 
composite; EQD2, equivalent dose in 2 Gy fractions; GTV, gross target volume; GU, genito-urinary; Gy, gray; IGRT, image-guided radiation therapy; 
IMRT, intensity modulated radiation therapy; IRB, institutional review board; LUTS, lower urinary tract symptoms; MID, minimally important differ-
ence; MRI, magnetic resonance imaging; PTV, planning target volume; QOL, quality of life; SBRT, stereotactic body radiation therapy; SD, standard 
deviation; SF-12, short form health survey-12-item.
TaBle 2 | Baseline quality of life characteristics.
Baseline aUa score % Patients (n = 204)
0–7 (Mild) 50%
8–19 (Moderate) 44%
≥20 (Severe) 6%
Baseline sF-12 score Mean (range) sD
PCS 50 (15.6–64.4) 8.76
MCS 57 (27.2–69.5) 6.71
Baseline ePic-26 dysuria (4b) Mean (range) sD MiD
96 (25–100) 11.7 5.9
July 2015 | Volume 5 | Article 1513
Janowski et al. SBRT-related dysuria
Frontiers in Oncology | www.frontiersin.org
critical structures, including the bladder and membranous urethra, 
was performed using Multiplan (Accuray Inc., Sunnyvale, CA, 
USA) inverse treatment planning. Treatment DVH goals included 
a maximum dose of 37 Gy to <5 cc of the bladder and <50% of 
the membranous urethra. While the prostatic urethra dose was 
not limited, we found that, by restricting the prescription isodose 
line to ≥75%, we were able to reduce the prostatic urethra dose to 
133% of the prescription dose (27, 28). Target position was verified 
every 30–60  s during each treatment using paired, orthogonal 
x-ray images (29).
Follow-Up and statistical analysis
Lower urinary tract symptoms (LUTS) and QOL data were 
collected for each patient prior to treatment and during routine 
follow-ups at 1, 3, 6, 9, and 12 months and then bi-annually. LUTS 
were assessed with the AUA Symptom Score, which ranges from 
0 to 35, with higher values representing worsening urinary symp-
toms (30). QOL data included completion of the Short Form-12 
Health Survey (SF-12) (31), the AUA Symptom Index (30), and 
the Expanded Prostate Cancer Index Composite (EPIC)-26 (32). 
Dysuria was assessed before and after treatment based on the 
patient reported response to Question 4b on the EPIC-26 (How 
big a problem, if any, has pain or burning with urination been for 
you during the last 4 weeks?). The EPIC summary scores for the 
dysuria domain range from 0 to 100, with lower values representing 
worsening dysuria. The responses to this question were grouped 
into three clinically relevant categories as previously described 
(33): moderate to big problem (0–40), very small to small problem 
(41–80), and no problem (81–100).
The EPIC and AUA score minimally important difference 
(MID) was defined as a change of one-half SD from the baseline 
(34). Statistical differences in dysuria and AUA scores were assessed 
using the Student’s t-test and chi-square analysis. Univariate and 
stepwise multivariate analyses were performed to assess dysuria 
correlation with demographic and treatment variables as well 
as with other urinary symptoms. QOL data time point patient 
response numbers are included in Table 3.
results
Between 2007 and 2010, 204 patients received SBRT monotherapy 
for treatment of localized prostate cancer, with a median clinical 
follow-up of 47  months (range, 10–72  months). Their baseline 
characteristics are summarized in Table  1. Our patients were 
ethnically diverse, including 54% Caucasian and 39% African 
American males. Median age was 69 years (range, 48–91 years). 
By D’Amico classification, 82 were low-, 105 intermediate-, and 17 
high-risk patients. Thirty patients (15%) also received androgen 
deprivation therapy (ADT). About 88% of the patients were treated 
with 36.25 Gy in five 7.25 Gy fractions.
Baseline QOL demographics are shown in Table 2. The majority 
of our treatment population reported either mild (50%) or mod-
erate (44%) baseline urinary bother, with a mean AUA score of 
8.48 ± 6.12 (range, 0–33). Pre-treatment mean EPIC dysuria assess-
ment revealed that our patient population had baseline minimal 
dysuria (score 96). Our patient group baseline SF-12 scores were 
comparable to those of a similarly aged general population (35).
TaBle 1 | Patient characteristics.
% N = 204
Age (years) Median 69 (48–91)
Age ≤ 60 13 27
60 < Age ≤ 70 45 92
Age > 70 42 85
Race White 54 111
Black 39 79
Other 7 14
Charlson comorbidity index CCI = 0 70 137
CCI = 1 21 42
CCI ≥ 2 9 18
Median prostate volume (cc) 39 (11.6–138.7)
BMI Median 27.5 
(15.02–44.96)
α1A inhibitor usage 18 35
Partner status Married/partnered 74 151
Not partnered 26 52
Risk groups (D’Amico) Low 40 82
Intermediate 52 105
High 8 17
ADT 15 30
SBRT dose 36.25 Gy 88 180
35 Gy 12 24
The prevalence of patient reported dysuria prior to and after 
treatment is shown in Table  3. At baseline, 12% of our cohort 
reported some level of dysuria, with 1% of those patients feeling it 
was a moderate to big problem. Levels of patient reported dysuria 
increased significantly following treatment (Figure 1A; Table 3), 
with 43% of patients reporting dysuria at 1 month (p < 0.0001), 
and 9% of patients reporting dysuria as being a moderate to big 
problem (Figure 1B; Table 3). There were two distinct peaks of 
moderate to severe dysuria bother at 1 month and at 6–12 months 
(Figures 1A,B), with 9% of patients reporting a late transient dysu-
ria flare that peaked at 6–9 months. While a low level of dysuria 
was seen through the first year of follow-up, our 18-month dysuria 
scores were virtually identical to the baseline values (Figure 1A; 
Table 3).
The median baseline AUA score of 7.5 significantly increased to 
11 at 1 month (p < 0.0001) and returned to 7 at 3 months (p = 0.54) 
(Figure 2A). Another small peak was seen at 12 months, where 
the median AUA increased from 7 to 8 (p = 0.36). Figure 2B and 
FigUre 2 | aUa changes after sBrT. (a) AUA values for the entire cohort prior to after treatment with SBRT. (B) AUA values in patients with (blue) and without 
(red) reported dysuria. AUA scores range from 0 to 35, with higher values representing worsening urinary symptoms.
TaBle 3 | Urinary dysuria bother following sBrT for prostate cancer.
start 1 3 6 9 12 18 24 30 36
No problem (%) 88 57 79 82 83 83 88 91 93 94
Very small-small (%) 11 34 20 13 13 15 10 8 6 6
Moderate-big (%) 1 9 1 5 4 2 2 1 1 0
Patient response (N) 203 200 198 186 185 178 165 175 171 157
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Table  4 show assessments of AUA scores in patients with and 
without reported dysuria, revealing that dysuria reporting patients 
had significantly higher AUA scores at all time points. In addition, 
the second AUA peak appeared to occur at 9  months in those 
patients reporting dysuria, consistent with the second late transient 
dysuria flare revealed in the EPIC questionnaire data (Figure 1).
FigUre 1 | ePic urinary dysuria quality of life changes after sBrT. (a) Epic 4b scores before and after SBRT treatment. (B) Patients were stratified to three 
groups: moderate–big (0–40), very small–small (41–80), and no problem (81–100).
Of the clinical and treatment variables in Table 5, the only pre-
dictors of dysuria at 1 month on multivariate analysis were the dose 
of radiation and the AUA score at 1 month. Initial AUA score did 
not predict for the development of dysuria. Patients who received 
36.25  Gy were significantly more likely to report dysuria than 
those that received 35 Gy. Table 6 shows the results of a stepwise 
TaBle 6 | Univariate and stepwise multivariate analysis for aUa 
correlation.
aUa questions p-Values Or 95% ci
Incomplete emptying 0.004a 3.42 1.50
Frequency 0.012a,b 13.52 1.78
Intermittency 0.774 1.09 0.59
Urgency 0.012a 3.05 1.27
Weak stream 0.642 1.18 0.58
Straining 0.0007a,b 2.85 1.56
Nocturia 0.343 2.15 0.44
aSignificant on univarariate analysis.
bSignificant on multivariate analysis.
TaBle 5 | Univariate and multivariate analysis.
Factors p-Values Or 95% ci
Age >70 0.213 0.68 0.37
Race 0.07 0.58 0.32
D’Amico’s risk groups 0.724 1.21 0.42
Prostate volume 0.486 0.99 0.98
Charlson comorbidity index 0.301 1.67 0.63
BMI 0.406 1.30 0.70
Dose 0.030a,b 3.99 1.15
Initial AUA 0.971 0.99 0.95
AUA at 1 month 0.001a,b 1.08 1.03
Initial α1A antagonist usage 0.581 0.80 0.36
α1A antagonist usage at 
1 month
0.152 1.54 0.85
aSignificant on univarariate analysis.
bSignificant on multivariate analysis.
TaBle 4 | average aUa after sBrT in patients with and without dysuria.
start 1 3 6 9 12 18 24 30 36
AUA without 
dysuria
8.07 10.13 7.81 7.04 7.84 8.71 7.7 7.73 7.57 7.87
AUA with dysuria 11.92 13.65 10.02 12.67 14.75 11.87 12.7 11.14 11.08 10.5
p-Value 0.011 <0.0001 0.033 <0.0001 0.0003 0.02 0.02 0.03 0.04 0.26
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multivariate analysis comparing the patient reported symptom 
of dysuria to the individual questions in the AUA questionnaire. 
While the AUA symptoms of incomplete emptying, frequency, 
urgency, and straining were significant on univariate analysis, only 
the AUA symptoms of frequency and strain significantly correlated 
with dysuria on stepwise multivariate analysis (Table 6).
Discussion
Dysuria is a well-known side effect after external beam radiation 
and brachytherapy (4); however, the incidence and severity of 
dysuria have not been sufficiently reported after SBRT. SBRT pros-
tate treatment is typically delivered in four to five large radiation 
fractions. Treatment safety is achieved via intra-fraction image 
guidance, which allows reduction of the CTV–PTV margin. A 
growing body of literature has shown SBRT to be safe and effica-
cious, with multiple single institutional studies (22, 36, 37) and 
a multi-institutional Phase I study (24) reporting high rates of 
biochemical control and low rates of grade 3 and higher toxicities 
with SBRT. Recently, a grouped series of over 1000 patients treated 
with 4–5 fraction SBRT reported a 5-year biochemical disease-free 
survival of 93% in all patients and 99% for the low-risk patients 
with favorable prognosis (38). Indeed, SBRT treatment utilization 
is increasing, with more patients preferring the convenience of 
hypofractionated radiation schedules (39).
While differences in patient reported dysuria may be attribut-
able to variability in measurement metrics, including time points 
interrogated, questionnaire phrasing, and severity levels reported, 
dysuria following SBRT was comparable to what has been reported 
following EBRT and brachytherapy (4). As previously described by 
McBride et al. (24), our mean AUA scores returned to baseline by 
3 months post-treatment. However, a minority of patients reported 
a clinically meaningful urinary symptom flare occurring greater 
than 6 months after completion of treatment. The peak of the AUA 
urinary symptom flare did correlate with the same time point as 
the small secondary increase in dysuria. Changes in AUA were 
significantly predictive of patient reported dysuria (Table 5), with 
the AUA measured symptoms of frequency and straining cor-
relating most closely to dysuria on stepwise multivariate analysis 
(Table 6).
Dose also correlated with report of dysuria (Table 5). In our 
opinion, dysuria may be exacerbated by the dose to the prostatic 
urethra and bladder neck in our relatively inhomogeneous plans, 
so we have modified our institutional protocol to limit dose to 
these critical structures. Specifically, we now restrict the maxi-
mum prostatic urethra dose to 110% of the prescription dose and 
prescribe to the ≥80% isodose line of the PTV. In addition, we 
have decreased the bladder neck dose by reducing the anterior/
superior PTV expansion to 3 mm. From our clinical experience, 
such modifications have reduced the incidence and severity of the 
late urinary symptom flare and patient reported dysuria without 
increasing the risk of biochemical failures (27).
Patients in our series generally reported a poor baseline 
urinary function and high alpha antagonist utilization prior to 
treatment, which is common in the older populations of most 
radiation therapy series (40–42). While initial alpha antagonist 
use did not predict for or against dysuria, other studies have shown 
that prophylactic tamsulosin use statistically lowered the dysuria 
severity score (9). To maximize patient comfort, it is now cur-
rently our institutional policy to initiate alpha antagonists prior 
to treatment.
Limitations in our study include our high rate of alpha-
antagonist utilization (43) and the poor correlation between 
alpha antagonist utilization and dysuria. Indeed, as we often initi-
ate alpha antagonists to maximize patient comfort, we may have 
masked the true incidence of SBRT patient reported dysuria (14) 
and may have given alpha antagonists to many patients with only 
mild dysuria. In addition, dysuria was commonly transient and 
the associated bother may have been missed due to the timing of 
questionnaire administration.
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conclusion
The rate and severity of dysuria following SBRT are comparable to 
patients treated with other radiation modalities. Dysuria signifi-
cantly correlates with dose of SBRT and AUA score, specifically the 
symptoms of frequency and straining. Our institution practice now 
includes prophylactic initiation or increase in alpha antagonists 
to symptomatically manage dysuria. These research findings add 
to a growing body of literature showing no significant detriment 
in quality of life measurements with SBRT treatment of localized 
prostate cancer.
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